The U.S. National Institutes of Health plans to award an exclusive license for promising medical technology that was funded by U.S. taxpayers to a company controlled by a Chinese billionaire.

In a notice posted on the Federal Register on Monday, the agency proposed giving patent rights for antibody drugs that would be used to treat liver cancer to Salubris Biotherapeutics, a division of a company that is largely owned by Ye Chenghai, a former mayor of Shenzhen, China, who is the 51st richest person in China, according to Forbes.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The NIH gives its technology away to pharma companies all the time at taxpayer expense. Are we supposed to. E outraged just because the owner of this particular company is Chinese? This type of taxpayer subsidization is done and is rewarded with high drug prices. Why not write an article about this?

    • Hi Jim,

      Thanks for your note. To your point, I have written about taxpayer funded research leading to high pricing for a drug – in this instance, Xtandi.

      If you do a search on our site – using the terms ‘Xtandi,’ ‘price,’ and ‘patent,’ you’ll see several stories about the controversy.

      Let me know what you think,
      ed at pharmalot

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy